{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:12:55Z","timestamp":1761520375537,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clcc.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T02:39:48Z","timestamp":1651718388000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ros\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-3542","authenticated-orcid":false,"given":"Frank","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-9115","authenticated-orcid":false,"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"World Health Organization \u2013 International Agency for Research on Cancer (IARC). All cancers. Available at: https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers. Accessed: May 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0001"},{"unstructured":"World Health Organization \u2013 International Agency for Research on Cancer (IARC). Colorectal cancer. Available at: https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers. Accessed: May 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0002"},{"unstructured":"Cancer Research UK Bowel cancer incidence statistics. Available at: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bowel-cancer\/survival#heading-Zero. Accessed: May 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0003"},{"unstructured":"Cancer Research UK Bowel cancer incidence statistics. Available at: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bowel-cancer\/incidence#heading-Three. Accessed: February 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0004"},{"unstructured":"American Cancer Society. Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/colorectal-cancer-facts-and-figures\/colorectal-cancer-facts-and-figures-2017-2019.pdf. Accessed: May 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0005"},{"issue":"3","key":"10.1016\/j.clcc.2022.04.002_bib0006","first-page":"1","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0007","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"unstructured":"Merck Sharp & Dohme B.V. KEYTRUDA Summary of Product Information. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed: August 11, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0008"},{"unstructured":"Bristol-Myers Squibb Pharma EEIG. OPDIVO Summary of Product Information. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed: August 11, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0009"},{"unstructured":"Bristol-Myers Squibb Pharma EEIG. YERVOY Summary of Product Information. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf. Accessed: August 11, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0010"},{"key":"10.1016\/j.clcc.2022.04.002_bib0011","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021\/007OL. Available at: http:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/kolorektales-karzinom\/. Accessed: September 29, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0012"},{"key":"10.1016\/j.clcc.2022.04.002_bib0013","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2022.04.002_bib0014","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0015","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131046","article-title":"High BRAF mutation frequency and marked survival differences in subgroups according to KRAS\/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort","volume":"10","author":"Sorbye","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2022.04.002_bib0017","first-page":"e69","article-title":"Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: A retrospective matched case-control study","volume":"17","author":"Kayhanian","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2022.04.002_bib0018","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2022.04.002_bib0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clcc.2022.04.002_bib0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2022.04.002_bib0021","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0022","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.04.002_bib0023","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0024","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF V600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2022.04.002_bib0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2022.04.002_bib0026","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.34.15_suppl.3544","article-title":"Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)","volume":"34","author":"Tabernero","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.04.002_bib0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"unstructured":"German Federal Joint Committee (G-BA). Overview on Regulatory Documents Concerning the Early Value Asessment of Drugs. Available at: https:\/\/www.g-ba.de\/downloads\/17-98-4977\/Fruehe-Nutzenbewertung_Gesetzesauftraege.pdf. Accessed: May 20, 2020.","key":"10.1016\/j.clcc.2022.04.002_bib0029"},{"unstructured":"German Federal Joint Committee (G-BA). Document template \u201cdossier for value assessment according to \u00a753a SGB V \u2013 module 4\u201d. 2019-02-21. Available at: https:\/\/www.g-ba.de\/downloads\/17-98-4825\/2019-02-21_Anl2_6_Modul4.pdf. Accessed: May 20, 2020.","key":"10.1016\/j.clcc.2022.04.002_bib0030"},{"unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). General Methods - Version 5.0. Available at: https:\/\/www.iqwig.de\/download\/General-Methods_Version-5-0.pdf. Accessed: October 7, 2020.","key":"10.1016\/j.clcc.2022.04.002_bib0031"},{"unstructured":"Pierre Fabre M\u00e9dicament. BRAFTOVI Summary of Product Information. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/braftovi-epar-product-information_en.pdf. Accessed: August 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0032"},{"unstructured":"Swissmedic. Swissmedic Journal 12\/2020. Available at: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/stab\/journal\/swissmedic-journal122020.pdf.download.pdf\/Swissmedic%20Journal%2012-2020.pdf. Accessed: August 24, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0033"},{"unstructured":"Federal Joint Committee. Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Encorafenib (New Therapeutic Indication: Metastatic Colorectal Cancer with a BRAF V600E Mutation after Prior Systemic Therapy, in Combination with Cetuximab). Available at: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/559\/#beschluesse. Accessed: August 25, 2021.","key":"10.1016\/j.clcc.2022.04.002_bib0034"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:55Z","timestamp":1761520135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282200041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S153300282200041X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.04.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}